Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
GXAI
Gaxos.ai
Sponsored
content by Gaxos.ai
JO
Jolt_Communications
Community Contributor
Gaxos.ai: Early-Stage AI Innovator in Gaming & Health
Key Takeaways Dual AI focus – Gaxos.ai builds AI-powered tools for game developers (via Unity integrations) and AI-driven health services under its RNK Health brand. First signs of commercial traction – After years of development, the company reported ~$194k in H1 2025 revenue, mainly from wellness pilot programs.
View narrative
US$2.21
FV
5.9% undervalued
intrinsic discount
119.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
29
users have followed this narrative
Updated
narrative
Microsoft
PI
PicaCoder
Community Contributor
After the AI Party: A Sobering Look at Microsoft's Future
The world has been captivated by the artificial intelligence boom, and no company has ridden the wave of investor enthusiasm quite like Microsoft. Buoyed by its strategic partnership with OpenAI and the integration of AI across its product ecosystem, the company's valuation has soared to unprecedented heights.
View narrative
US$500.00
FV
1.4% overvalued
intrinsic discount
6.75%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
12
users have commented on this narrative
25
users have followed this narrative
12 days ago
author updated this narrative
Amazon.com
ZW
Zwfis
Community Contributor
Amazon's Future Rises as Stock Price Falls: A Long-Term Investment Vision
Amazon is a stock I am very interested in right now especially with the recent price drops that it has been experiencing since its 2Q25 results. A summary of Amazon as stated by Fiscal.ai: "Amazon.com, Inc.
View narrative
US$234.75
FV
2.5% undervalued
intrinsic discount
13.60%
Revenue growth p.a.
Set Fair Value
20
users have liked this narrative
7
users have commented on this narrative
24
users have followed this narrative
New
narrative
Verve Group
TI
TibiT
Community Contributor
Verve Group: A Tale of Three Futures
Verve Group stands at a critical juncture. After a history of explosive growth, the company has been hit by significant operational headwinds, primarily the difficult and costly migration to a unified technology platform and unfavorable currency exchange rates.
View narrative
€4.02
FV
44.5% undervalued
intrinsic discount
8.50%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
Updated
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Global Water Resources
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Sun Belt Urban Growth And Drought Will Drive Water Demand
Key Takeaways Strategic acquisitions and advanced water management position the company for rapid margin expansion, outsized earnings growth, and structural pricing power in high-demand regions. Strong policy tailwinds and infrastructure investments drive above-trend demand, attracting sustainable capital and supporting high-return, long-term growth opportunities.
View narrative
US$18.00
FV
44.3% undervalued
intrinsic discount
6.88%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Chicago Atlantic Real Estate Finance
AN
AnalystHighTarget
Consensus Narrative from 4 Analysts
Expanding Cannabis Legalization Will Transform Credit Markets Despite Risks
Key Takeaways Unique scale and first-mover advantage in specialty cannabis lending allow for rapid pipeline growth, strong pricing power, and sustained industry-leading profit margins. Broad, flexible credit facilities and operational efficiencies position the company to capture outsized growth as cannabis legalization expands and refinancing needs accelerate.
View narrative
US$20.00
FV
27.9% undervalued
intrinsic discount
5.70%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Limoneira
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Precision Agriculture Will Unlock Global Healthy Produce Markets
Key Takeaways Strategic partnerships, technological innovation, and an integrated supply chain position Limoneira to outperform peers in efficiency, margin growth, and global market reach. Early avocado productivity, asset monetization, and strengthened financial flexibility accelerate growth opportunities and enable rapid response to surging demand and industry consolidation.
View narrative
US$31.00
FV
46.7% undervalued
intrinsic discount
-9.49%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Sensus Healthcare
AN
AnalystHighTarget
Consensus Narrative from 5 Analysts
Growing Global Aging Will Expand Noninvasive Treatment Markets
Key Takeaways Favorable reimbursement changes and international certifications could rapidly unlock significant sales growth, recurring revenue, and margin recovery across key domestic and global markets. Sensus's technology, partnerships, and exposure to rising skin cancer incidence strategically position it for sustained, high-margin revenue and share gains in expanding oncology settings.
View narrative
US$10.00
FV
67.5% undervalued
intrinsic discount
21.05%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Universal Health Services
AN
AnalystLowTarget
Consensus Narrative from 16 Analysts
Lower Medicaid Payments And Rising Costs Will Erode Margins
Key Takeaways Increased reliance on government payers and new legislation will drive lower reimbursement rates and greater exposure to policy risks, tightening margins over time. Persistent labor cost pressures and shifts to outpatient and telehealth care threaten revenue growth and undermine historical earnings stability.
View narrative
US$165.00
FV
12.5% overvalued
intrinsic discount
4.84%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Crexendo
AN
AnalystHighTarget
Consensus Narrative from 7 Analysts
Digital Transformation And Remote Work Will Drive Cloud Evolution
Key Takeaways Rapid share gains, operational efficiencies, and strategic carrier partnerships position Crexendo for accelerated growth and margin expansion in a changing cloud communications market. Innovation through AI features, open integrations, and global expansion supports long-term outperformance in recurring software revenue and profitability.
View narrative
US$10.74
FV
43.2% undervalued
intrinsic discount
12.34%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
CytomX Therapeutics
AN
AnalystHighTarget
Consensus Narrative from 6 Analysts
KEYTRUDA And CX-2051 Trials Will Expand Immuno-Oncology Reach Despite Risks
Key Takeaways Broad applicability of CytomX's pipeline and innovative platform positions it for rapid market penetration, larger addressable revenue, and increased immuno-oncology market share versus expectations. Strategic partnerships, capital efficiency, and technological edge strengthen non-dilutive revenue prospects and make CytomX an attractive acquisition target, supporting sustained margin expansion.
View narrative
US$8.00
FV
73.5% undervalued
intrinsic discount
-10.36%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
EMCOR Group
AN
AnalystLowTarget
Consensus Narrative from 6 Analysts
Rising Automation And Tightening Regulations Will Erode Margins
Key Takeaways Accelerating automation, prefabrication, and modular trends threaten EMCOR's traditional service demand, recurring revenues, and long-term growth prospects. Regulatory pressures and regional market dependence increase margin risks and earnings volatility, especially amid rising labor costs and sustainability mandates.
View narrative
US$510.73
FV
19.5% overvalued
intrinsic discount
7.41%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
QuickLogic
AN
AnalystHighTarget
Consensus Narrative from 2 Analysts
Edge AI And IoT Trends Will Expand eFPGA Licensing
Key Takeaways Accelerated adoption in defense, Edge AI, and custom silicon markets positions QuickLogic to capture dominant share, command premium pricing, and drive strong revenue growth. Integration of open-source tools and deep ecosystem partnerships fosters recurring platform revenue, expanding the customer base and strengthening long-term margin visibility.
View narrative
US$10.00
FV
43.5% undervalued
intrinsic discount
33.54%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
New
narrative
Value any company in seconds
Popular companies